市場調査レポート

商品コード

1298392

制酸剤市場：作用機序別、製剤タイプ別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Antacids Market By Mechanism of Action, By Formulation Type, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2023年04月01日 | 発行: Allied Market Research

| ページ情報: 英文 249 Pages | 納期: 2～3営業日

価格

PDF (Single User License)

USD 5,730 898,234円

レポートPDFを1つのPCでご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回だけ可能です。印刷したレポートの利用もPDFのライセンス保持者になります。回覧のための複製も原則NGです。

PDF (5-user License)

USD 6,450 1,011,102円

レポートPDFを5名でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回可能です。印刷したレポートの利用もPDFのライセンス保持者5名となります。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,504,896円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

制酸剤市場は、2022年に66億7,882万米ドルと評価され、2023年から2032年にかけて3.1％のCAGRを示し、2032年には90億6,847万米ドルに達すると推定されます。

制酸剤は、胸焼けや消化不良を緩和するために使用される薬です。これらの薬は、胃で分泌される塩酸の量を減らすことで作用します。胃は消化を行うために塩酸を分泌します。酸は腐食性があるため、粘膜のバリアが胃の粘膜が侵食されないように保護しています。しかし、酸の逆流や粘膜バリアに関連する問題があると、胸焼けが起こることがあります。このような場合、制酸剤を使用して胃に存在する酸を中和し、水や塩などの中性の物質を生成します。これによって胃酸が減り、胸やけや消化不良の症状が緩和されます。

制酸剤には錠剤、液剤など様々な種類があり、味や強さも様々です。これらの薬は適量であれば安全に使用でき、軽い症状には効果的です。制酸剤に含まれる一般的な成分には、水酸化アルミニウム、水酸化マグネシウム、炭酸カルシウム、炭酸水素ナトリウムなどがあります。制酸剤の中には、シメチコンと炭酸カルシウムの組み合わせや、水酸化マグネシウムとシメチコンの組み合わせなど、ガスや膨満感を和らげるために使用されるものもあります。

世界の制酸剤市場の成長は、酸関連疾患の有病率の増加、市販（OTC）制酸剤の利便性と入手しやすさ、セルフメディケーションを行う患者の増加によってもたらされます。酸関連疾患には、胃食道逆流症（GERD）、消化性潰瘍、消化不良症など、胃酸の過剰分泌によって引き起こされるさまざまな胃腸障害が含まれます。これらの酸関連疾患の有病率の増加は、制酸剤市場の主要な促進要因となっています。例えば、2020年の国立医学図書館によると、6,000万人以上のアメリカ人が少なくとも月に一度は胸焼けを経験しています。

しかし、制酸剤の過剰使用は様々な副作用を引き起こし、市場の成長を阻害する可能性があります。例えば、制酸剤はナトリウム、カリウム、カルシウムといった体内の電解質レベルに影響を及ぼす可能性があります。また、制酸剤の長期使用は腎臓に負担をかけ、腎結石や腎不全などの問題を引き起こす可能性があります。加えて、酸逆流や胃食道逆流症（GERD）などの疾患や治療法に対する認識が低開発国の人々の間で低いことも、市場の主な抑制要因となっています。

その一方で、費用対効果が高く副作用の少ない幅広い薬剤の開発に注力するメーカーの増加は、市場成長に有利な機会を提供すると予想されます。例えば、アルケム・ラボラトリーズは、ミント、オレンジ、サウンフなど様々なフレーバーのOmee MPSリキッドや、同じフレーバーのOmeeチュアタブを提供しています。これらの制酸剤は手頃な価格であるため、発展途上国や先進国で採用が増加しています。

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資ポケット
ポーターのファイブフォース分析
- 供給企業の交渉力
- 買い手の交渉力
- 代替品の脅威
- 新規参入業者の脅威
- 競合の激しさ
市場力学
- 促進要因
  - 酸逆流とGERDの有病率の増加
  - OTC制酸剤の容易な入手可能性
  - 老年人口における制酸剤需要の急増
- 阻害要因
  - 制酸剤の使用に関する制限
  - 代替治療の出現
- 機会
  - 世界人口のライフスタイルの急速な変化
COVID-19市場への影響分析

第4章制酸剤市場：作用機序別

概要
- 市場規模と予測
全身性制酸剤
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
非全身性制酸剤
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別

第5章制酸剤市場：製剤タイプ別

概要
- 市場規模および予測
錠剤
- 主要市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
液体
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
その他
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別

第6章制酸剤市場：流通チャネル別

概要
- 市場規模および予測
病院薬局
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
ドラッグストア・小売薬局
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
オンラインプロバイダー
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別

第7章制酸剤市場：地域別

概要
- 市場規模・予測：地域別
北米
- 主要動向と機会
- 市場規模・予測：作用機序別
- 市場規模・予測：製剤タイプ別
- 市場規模・予測：流通チャネル別
- 市場規模・予測：国別
  - 米国
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：作用機序別
  - 市場規模・予測：製剤タイプ別
  - 市場規模・予測：流通チャネル別
  - カナダ
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：作用機序別
  - 市場規模・予測：製剤タイプ別
  - 市場規模・予測：流通チャネル別
  - メキシコ
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：作用機序別
  - 市場規模・予測：製剤タイプ別
  - 市場規模・予測：流通チャネル別
欧州
- 主要動向と機会
- 市場規模・予測：作用機序別
- 市場規模・予測：製剤タイプ別
- 市場規模・予測：流通チャネル別
- 市場規模・予測：国別
  - ドイツ
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：作用機序別
  - 市場規模・予測：製剤タイプ別
  - 市場規模・予測：流通チャネル別
  - フランス
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：作用機序別
  - 市場規模・予測：製剤タイプ別
  - 市場規模・予測：流通チャネル別
  - 英国
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：作用機序別
  - 市場規模・予測：製剤タイプ別
  - 市場規模・予測：流通チャネル別
  - イタリア
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：作用機序別
  - 市場規模・予測：製剤タイプ別
  - 市場規模・予測：流通チャネル別
  - スペイン
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：作用機序別
  - 市場規模・予測：製剤タイプ別
  - 市場規模・予測：流通チャネル別
  - その他欧州
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：作用機序別
  - 市場規模・予測：製剤タイプ別
  - 市場規模・予測：流通チャネル別
アジア太平洋地域
- 主要動向と機会
- 市場規模・予測：作用機序別
- 市場規模・予測：製剤タイプ別
- 市場規模・予測：流通チャネル別
- 市場規模・予測：国別
  - 日本
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：作用機序別
  - 市場規模・予測：製剤タイプ別
  - 市場規模・予測：流通チャネル別
  - 中国
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：作用機序別
  - 市場規模・予測：製剤タイプ別
  - 市場規模・予測：流通チャネル別
  - インド
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：作用機序別
  - 市場規模・予測：製剤タイプ別
  - 市場規模・予測：流通チャネル別
  - オーストラリア
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：作用機序別
  - 市場規模・予測：製剤タイプ別
  - 市場規模・予測：流通チャネル別
  - 韓国
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：作用機序別
  - 市場規模・予測：製剤タイプ別
  - 市場規模・予測：流通チャネル別
  - その他アジア太平洋地域
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：作用機序別
  - 市場規模・予測：製剤タイプ別
  - 市場規模・予測：流通チャネル別
ラテンアメリカ・中東・アフリカ
- 主要動向と機会
- 市場規模・予測：作用機序別
- 市場規模・予測：製剤タイプ別
- 市場規模・予測：流通チャネル別
- 市場規模・予測：国別
  - ブラジル
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：作用機序別
  - 市場規模・予測：製剤タイプ別
  - 市場規模・予測：流通チャネル別
  - サウジアラビア
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：作用機序別
  - 市場規模・予測：製剤タイプ別
  - 市場規模・予測：流通チャネル別
  - 南アフリカ
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：作用機序別
  - 市場規模・予測：製剤タイプ別
  - 市場規模・予測：流通チャネル別
  - その他の地域
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：作用機序別
  - 市場規模・予測：製剤タイプ別
  - 市場規模・予測：流通チャネル別

第8章競合情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
トップ企業のポジショニング、2022年

第9章企業プロファイル

Bayer AG
Alkem Laboratories Ltd.
Cipla Ltd
Pfizer Inc.
WellSpring Pharmaceutical Corporation
Haleon plc
Prestige Consumer Healthcare Inc.
Reckitt Benckiser Group PLC
Infirst Healthcare Inc.
Abbott Laboratories

図表

LIST OF TABLES

TABLE 01. GLOBAL ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 02. ANTACIDS MARKET FOR SYSTEMIC ANTACIDS , BY REGION, 2022-2032 ($MILLION)
TABLE 03. ANTACIDS MARKET FOR NON-SYSTEMIC ANTACIDS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. GLOBAL ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 05. ANTACIDS MARKET FOR TABLETS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. ANTACIDS MARKET FOR LIQUIDS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. ANTACIDS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 09. ANTACIDS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 10. ANTACIDS MARKET FOR DRUG STORES AND RETAIL PHARMACIES , BY REGION, 2022-2032 ($MILLION)
TABLE 11. ANTACIDS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. ANTACIDS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA ANTACIDS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 17. U.S. ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 18. U.S. ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 19. U.S. ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 20. CANADA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 21. CANADA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 22. CANADA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 23. MEXICO ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 24. MEXICO ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 25. MEXICO ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 26. EUROPE ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 27. EUROPE ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 28. EUROPE ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 29. EUROPE ANTACIDS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 30. GERMANY ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 31. GERMANY ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 32. GERMANY ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 33. FRANCE ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 34. FRANCE ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 35. FRANCE ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 36. UK ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 37. UK ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 38. UK ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 39. ITALY ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 40. ITALY ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 41. ITALY ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 42. SPAIN ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 43. SPAIN ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 44. SPAIN ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 45. REST OF EUROPE ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 48. ASIA-PACIFIC ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC ANTACIDS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 52. JAPAN ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 53. JAPAN ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 54. JAPAN ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 55. CHINA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 56. CHINA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 57. CHINA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 58. INDIA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 59. INDIA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 60. INDIA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 62. AUSTRALIA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 63. AUSTRALIA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 64. SOUTH KOREA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 70. LAMEA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 71. LAMEA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 72. LAMEA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 73. LAMEA ANTACIDS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 74. BRAZIL ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 75. BRAZIL ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 76. BRAZIL ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 77. SAUDI ARABIA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 78. SAUDI ARABIA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 80. SOUTH AFRICA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 81. SOUTH AFRICA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 83. REST OF LAMEA ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 84. REST OF LAMEA ANTACIDS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 86. BAYER AG: KEY EXECUTIVES
TABLE 87. BAYER AG: COMPANY SNAPSHOT
TABLE 88. BAYER AG: PRODUCT SEGMENTS
TABLE 89. BAYER AG: PRODUCT PORTFOLIO
TABLE 90. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
TABLE 91. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 92. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
TABLE 93. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 94. CIPLA LTD: KEY EXECUTIVES
TABLE 95. CIPLA LTD: COMPANY SNAPSHOT
TABLE 96. CIPLA LTD: PRODUCT SEGMENTS
TABLE 97. CIPLA LTD: PRODUCT PORTFOLIO
TABLE 98. PFIZER INC.: KEY EXECUTIVES
TABLE 99. PFIZER INC.: COMPANY SNAPSHOT
TABLE 100. PFIZER INC.: PRODUCT SEGMENTS
TABLE 101. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 102. WELLSPRING PHARMACEUTICAL CORPORATION: KEY EXECUTIVES
TABLE 103. WELLSPRING PHARMACEUTICAL CORPORATION: COMPANY SNAPSHOT
TABLE 104. WELLSPRING PHARMACEUTICAL CORPORATION: PRODUCT SEGMENTS
TABLE 105. WELLSPRING PHARMACEUTICAL CORPORATION: PRODUCT PORTFOLIO
TABLE 106. HALEON PLC: KEY EXECUTIVES
TABLE 107. HALEON PLC: COMPANY SNAPSHOT
TABLE 108. HALEON PLC: PRODUCT SEGMENTS
TABLE 109. HALEON PLC: PRODUCT PORTFOLIO
TABLE 110. PRESTIGE CONSUMER HEALTHCARE INC.: KEY EXECUTIVES
TABLE 111. PRESTIGE CONSUMER HEALTHCARE INC.: COMPANY SNAPSHOT
TABLE 112. PRESTIGE CONSUMER HEALTHCARE INC.: PRODUCT SEGMENTS
TABLE 113. PRESTIGE CONSUMER HEALTHCARE INC.: PRODUCT PORTFOLIO
TABLE 114. RECKITT BENCKISER GROUP PLC: KEY EXECUTIVES
TABLE 115. RECKITT BENCKISER GROUP PLC: COMPANY SNAPSHOT
TABLE 116. RECKITT BENCKISER GROUP PLC: PRODUCT SEGMENTS
TABLE 117. RECKITT BENCKISER GROUP PLC: PRODUCT PORTFOLIO
TABLE 118. INFIRST HEALTHCARE INC.: KEY EXECUTIVES
TABLE 119. INFIRST HEALTHCARE INC.: COMPANY SNAPSHOT
TABLE 120. INFIRST HEALTHCARE INC.: PRODUCT SEGMENTS
TABLE 121. INFIRST HEALTHCARE INC.: PRODUCT PORTFOLIO
TABLE 122. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 123. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 124. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 125. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. ANTACIDS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF ANTACIDS MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN ANTACIDS MARKET (2023-2032)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW THREAT OF NEW ENTRANTS
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALANTACIDS MARKET
FIGURE 10. ANTACIDS MARKET, BY MECHANISM OF ACTION, 2022(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR SYSTEMIC ANTACIDS , BY COUNTRY 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR NON-SYSTEMIC ANTACIDS, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. ANTACIDS MARKET, BY FORMULATION TYPE, 2022(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR TABLETS, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR LIQUIDS, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. ANTACIDS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR DRUG STORES AND RETAIL PHARMACIES , BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ANTACIDS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. ANTACIDS MARKET BY REGION, 2022
FIGURE 22. U.S. ANTACIDS MARKET, 2022-2032 ($MILLION)
FIGURE 23. CANADA ANTACIDS MARKET, 2022-2032 ($MILLION)
FIGURE 24. MEXICO ANTACIDS MARKET, 2022-2032 ($MILLION)
FIGURE 25. GERMANY ANTACIDS MARKET, 2022-2032 ($MILLION)
FIGURE 26. FRANCE ANTACIDS MARKET, 2022-2032 ($MILLION)
FIGURE 27. UK ANTACIDS MARKET, 2022-2032 ($MILLION)
FIGURE 28. ITALY ANTACIDS MARKET, 2022-2032 ($MILLION)
FIGURE 29. SPAIN ANTACIDS MARKET, 2022-2032 ($MILLION)
FIGURE 30. REST OF EUROPE ANTACIDS MARKET, 2022-2032 ($MILLION)
FIGURE 31. JAPAN ANTACIDS MARKET, 2022-2032 ($MILLION)
FIGURE 32. CHINA ANTACIDS MARKET, 2022-2032 ($MILLION)
FIGURE 33. INDIA ANTACIDS MARKET, 2022-2032 ($MILLION)
FIGURE 34. AUSTRALIA ANTACIDS MARKET, 2022-2032 ($MILLION)
FIGURE 35. SOUTH KOREA ANTACIDS MARKET, 2022-2032 ($MILLION)
FIGURE 36. REST OF ASIA-PACIFIC ANTACIDS MARKET, 2022-2032 ($MILLION)
FIGURE 37. BRAZIL ANTACIDS MARKET, 2022-2032 ($MILLION)
FIGURE 38. SAUDI ARABIA ANTACIDS MARKET, 2022-2032 ($MILLION)
FIGURE 39. SOUTH AFRICA ANTACIDS MARKET, 2022-2032 ($MILLION)
FIGURE 40. REST OF LAMEA ANTACIDS MARKET, 2022-2032 ($MILLION)
FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 45. COMPETITIVE DASHBOARD
FIGURE 46. COMPETITIVE HEATMAP: ANTACIDS MARKET
FIGURE 47. TOP PLAYER POSITIONING, 2022
FIGURE 48. BAYER AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 49. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 50. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 51. ALKEM LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 52. ALKEM LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 53. CIPLA LTD: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 54. CIPLA LTD: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 55. CIPLA LTD: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 56. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 57. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 58. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 59. HALEON PLC: NET SALES, 2021-2021 ($MILLION)
FIGURE 60. PRESTIGE CONSUMER HEALTHCARE INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 61. PRESTIGE CONSUMER HEALTHCARE INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 62. PRESTIGE CONSUMER HEALTHCARE INC.: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 63. RECKITT BENCKISER GROUP PLC: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 64. RECKITT BENCKISER GROUP PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 65. RECKITT BENCKISER GROUP PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 66. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
FIGURE 67. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 68. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)

Product Code: A10281

The antacids market valued for $6,678.82 million in 2022 and is estimated to reach $9,068.47 million by 2032, exhibiting a CAGR of 3.1% from 2023 to 2032.

Antacid is a medication that is used to alleviate heartburn and indigestion. These medications act by reducing the amount of hydrochloric acid secreted in the stomach. The stomach secretes hydrochloric acid to carry out the digestion process. As the acid is corrosive, a mucous barrier protects the lining of the stomach from being eroded. However, acid reflux or issues associated with the mucous barrier can result in heartburn. This In such cases, antacids are used to neutralize the acid present in the stomach to produce a neutral substance, such as water or salt. This reduces the acidity in the stomach and relieves symptoms of heartburn and indigestion.

Antacids are available in various types of formulations such as tablets, liquids, and others, along with a range of flavors and strengths. These medications are safe to use in moderation and can be effective for mild symptoms. Common ingredients in antacids include aluminum hydroxide, magnesium hydroxide, calcium carbonate, and sodium bicarbonate. Some antacids are given in combination such as simethicone along with calcium carbonate or magnesium hydroxide and simethicone, which is used to relieve gas and bloating.

The growth of the global antacids market is driven increase in prevalence of acid-related conditions, convenience & accessibility of over-the-counter (OTC) antacids, and rise in number of patients engaging in self-medication. Acid-related conditions involve a range of gastrointestinal disorders that are caused by excessive secretion of gastric acid, such as gastroesophageal reflux disease (GERD), peptic ulcers, and dyspepsia. Increase in prevalence of these acid-related conditions acts as a major driver of the antacids market. For instance, according to the National Library of Medicine in 2020, more than 60 million Americans experience heartburn at least once a month.

However, excessive use of antacids leads to a range of side effects that potentially hinder the growth of the market. For instance, antacids may affect the levels of electrolytes in the body, such as sodium, potassium, and calcium. In addition, prolonged use of antacids can put strain on the kidneys, leading to problems such as kidney stones or renal failure. In addition, low awareness about acid reflux, gastroesophageal reflux disease (GERD), and other conditions and available treatment among the population of underdeveloped countries acts as a key restraint of the market.

On the contrary, increase in focus of manufacturers to develop cost-effective and wide range of medications with less side effects is expected to offer lucrative opportunities for the market growth. For instance, Alkem Laboratories offers Omee MPS liquid, which is available in a range of flavors such as mint, orange, and saunf as well as Omee Chewtabs, which are available in the same flavors. These antacids are affordable, and thus, have witnessed increased adoption in developing and developed countries.

In addition, people in underdeveloped countries are becoming aware about antacid medications available in the market and their use in managing acidity and other acid-related conditions. This is anticipated to boost the market during the forecast period. In addition, emerging countries in Asia-Pacific and LAMEA are characterized by presence of large population base along with rapid economic growth and increase in healthcare expenditure. All these factors are anticipated to increase the demand for antacids in these regions, thereby boosting the global market growth.

The global antacids market is segmented into medication type, formulation type, distribution channel, and region. By product, the market is bifurcated into systemic antacids and non-systemic antacids. On the basis of formulation type, it is categorized into tablet, liquids, and others. By distribution channel, it is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the Abbott Laboratories, Pfizer Inc., Prestige Consumer Healthcare Inc., Cipla Ltd, Reckitt Benckiser Group PLC, Haleon plc, Bayer AG, Alkem Laboratories Ltd., WellSpring Pharmaceutical Corporation and Infirst Healthcare Inc.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antacids market analysis from 2022 to 2032 to identify the prevailing antacids market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the antacids market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global antacids market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Mechanism of Action

Systemic Antacids
Non-systemic Antacids

By Formulation Type

Tablets
Liquids
Others

By Distribution channel

Hospital pharmacies
Drug stores and retail pharmacies
Online providers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Abbott Laboratories
Alkem Laboratories Ltd.
Bayer AG
Cipla Ltd
Haleon plc
Infirst Healthcare Inc.
Pfizer Inc.
Prestige Consumer Healthcare Inc.
Reckitt Benckiser Group PLC
WellSpring Pharmaceutical Corporation

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increase in prevalence of acid reflux and GERD
  - 3.4.1.2. Easy availability of OTC antacids
  - 3.4.1.3. Surge in demand for antacids among geriatric population

3.4.2. Restraints
- 3.4.2.1. Limitations related to use of antacids
- 3.4.2.2. Emergence of alternative treatments

3.4.3. Opportunities
- 3.4.3.1. Rapidly changing lifestyle of global population

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: ANTACIDS MARKET, BY MECHANISM OF ACTION

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Systemic Antacids
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Non-systemic Antacids
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country

CHAPTER 5: ANTACIDS MARKET, BY FORMULATION TYPE

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Tablets
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Liquids
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: ANTACIDS MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Drug stores and retail pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Online providers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: ANTACIDS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Mechanism of Action
- 7.2.3. Market size and forecast, by Formulation Type
- 7.2.4. Market size and forecast, by Distribution channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Mechanism of Action
  - 7.2.5.1.3. Market size and forecast, by Formulation Type
  - 7.2.5.1.4. Market size and forecast, by Distribution channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Mechanism of Action
  - 7.2.5.2.3. Market size and forecast, by Formulation Type
  - 7.2.5.2.4. Market size and forecast, by Distribution channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Mechanism of Action
  - 7.2.5.3.3. Market size and forecast, by Formulation Type
  - 7.2.5.3.4. Market size and forecast, by Distribution channel
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Mechanism of Action
- 7.3.3. Market size and forecast, by Formulation Type
- 7.3.4. Market size and forecast, by Distribution channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Mechanism of Action
  - 7.3.5.1.3. Market size and forecast, by Formulation Type
  - 7.3.5.1.4. Market size and forecast, by Distribution channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Mechanism of Action
  - 7.3.5.2.3. Market size and forecast, by Formulation Type
  - 7.3.5.2.4. Market size and forecast, by Distribution channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Mechanism of Action
  - 7.3.5.3.3. Market size and forecast, by Formulation Type
  - 7.3.5.3.4. Market size and forecast, by Distribution channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Mechanism of Action
  - 7.3.5.4.3. Market size and forecast, by Formulation Type
  - 7.3.5.4.4. Market size and forecast, by Distribution channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Mechanism of Action
  - 7.3.5.5.3. Market size and forecast, by Formulation Type
  - 7.3.5.5.4. Market size and forecast, by Distribution channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Mechanism of Action
  - 7.3.5.6.3. Market size and forecast, by Formulation Type
  - 7.3.5.6.4. Market size and forecast, by Distribution channel
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Mechanism of Action
- 7.4.3. Market size and forecast, by Formulation Type
- 7.4.4. Market size and forecast, by Distribution channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Mechanism of Action
  - 7.4.5.1.3. Market size and forecast, by Formulation Type
  - 7.4.5.1.4. Market size and forecast, by Distribution channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Mechanism of Action
  - 7.4.5.2.3. Market size and forecast, by Formulation Type
  - 7.4.5.2.4. Market size and forecast, by Distribution channel
  - 7.4.5.3. India
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Mechanism of Action
  - 7.4.5.3.3. Market size and forecast, by Formulation Type
  - 7.4.5.3.4. Market size and forecast, by Distribution channel
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Mechanism of Action
  - 7.4.5.4.3. Market size and forecast, by Formulation Type
  - 7.4.5.4.4. Market size and forecast, by Distribution channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Mechanism of Action
  - 7.4.5.5.3. Market size and forecast, by Formulation Type
  - 7.4.5.5.4. Market size and forecast, by Distribution channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Mechanism of Action
  - 7.4.5.6.3. Market size and forecast, by Formulation Type
  - 7.4.5.6.4. Market size and forecast, by Distribution channel
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Mechanism of Action
- 7.5.3. Market size and forecast, by Formulation Type
- 7.5.4. Market size and forecast, by Distribution channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Mechanism of Action
  - 7.5.5.1.3. Market size and forecast, by Formulation Type
  - 7.5.5.1.4. Market size and forecast, by Distribution channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Mechanism of Action
  - 7.5.5.2.3. Market size and forecast, by Formulation Type
  - 7.5.5.2.4. Market size and forecast, by Distribution channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Mechanism of Action
  - 7.5.5.3.3. Market size and forecast, by Formulation Type
  - 7.5.5.3.4. Market size and forecast, by Distribution channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Mechanism of Action
  - 7.5.5.4.3. Market size and forecast, by Formulation Type
  - 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Bayer AG
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
9.2. Alkem Laboratories Ltd.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. Cipla Ltd
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. Pfizer Inc.
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
9.5. WellSpring Pharmaceutical Corporation
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
9.6. Haleon plc
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
9.7. Prestige Consumer Healthcare Inc.
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. Reckitt Benckiser Group PLC
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
9.9. Infirst Healthcare Inc.
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
9.10. Abbott Laboratories
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance

制酸剤市場：作用機序別、製剤タイプ別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Antacids Market By Mechanism of Action, By Formulation Type, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章制酸剤市場：作用機序別

第5章制酸剤市場：製剤タイプ別

第6章制酸剤市場：流通チャネル別

第7章制酸剤市場：地域別

第8章競合情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Mechanism of Action

By Formulation Type

By Distribution channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: ANTACIDS MARKET, BY MECHANISM OF ACTION

CHAPTER 5: ANTACIDS MARKET, BY FORMULATION TYPE

CHAPTER 6: ANTACIDS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: ANTACIDS MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

制酸剤市場：作用機序別、製剤タイプ別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Antacids Market By Mechanism of Action, By Formulation Type, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 制酸剤市場：作用機序別

第5章 制酸剤市場：製剤タイプ別

第6章 制酸剤市場：流通チャネル別

第7章 制酸剤市場：地域別

第8章 競合情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Mechanism of Action

By Formulation Type

By Distribution channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: ANTACIDS MARKET, BY MECHANISM OF ACTION

CHAPTER 5: ANTACIDS MARKET, BY FORMULATION TYPE

CHAPTER 6: ANTACIDS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: ANTACIDS MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章制酸剤市場：作用機序別

第5章制酸剤市場：製剤タイプ別

第6章制酸剤市場：流通チャネル別

第7章制酸剤市場：地域別

第8章競合情勢

第9章企業プロファイル